01:21 , Jan 12, 2018 |  BC Innovations  |  Translation in Brief

In the twenties

A...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Company News

BioNovion, Aduro Biotech deal

Aduro will also gain BioNovion’s antibody production technology, which is based on the clonal expansion of cultured B cells isolated from the spleen or lymph nodes of immunized mice, and five bispecific antibodies against undisclosed...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Clinical News

Varlilumab: Phase I/II started

Celldex began an open-label, U.S. Phase I/II trial to evaluate 0.1, 1 and 10 mg/kg IV varlilumab every 2 weeks for 24 or 32 weeks plus 3 mg/kg IV Opdivo nivolumab from Bristol-Myers Squibb Co....
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

Varlilumab: Additional Phase I data

Data from 16 patients with metastatic melanoma in an expansion cohort of an open-label, dose-escalation, U.S. Phase I trial showed that once-weekly 3 mg/kg varlilumab led to 3 cases of stable disease and a progression-free...
07:00 , May 19, 2014 |  BC Week In Review  |  Company News

Celldex, Bristol-Myers deal

Celldex partnered with Bristol-Myers Squibb in an exclusive deal to evaluate combinations of anti- PD-1 receptor ( PDCD1 ; PD-1; CD279 ) antagonist antibodies with anti- CD27 agonist antibodies. Under the deal, Celldex will run...
01:12 , May 15, 2014 |  BC Extra  |  Top Story

BMS, Celldex to study nivolumab, CDX-1127

Celldex Therapeutics Inc. (NASDAQ:CLDX) jumped $3.34 (27%) to $15.74 on Wednesday after announcing an exclusive deal with Bristol-Myers Squibb Co. (NYSE:BMY) to evaluate combinations of anti- PD-1 receptor ( PDCD1 ; PD-1; CD279 ) antagonist...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Clinical News

CDX-1127: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in patients with relapsed or refractory lymphoid malignancies or solid tumors showed that CDX-1127 was well tolerated and led to 1 complete response in a patient with stage...
08:00 , Jan 26, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic myelogenous leukemia (CML) CD27; CD70 (CD27L) Cell culture and mouse studies suggest blocking CD27-CD70 interactions could help treat CML. In...
08:00 , Nov 14, 2011 |  BC Week In Review  |  Clinical News

CDX-1127: Phase I started

Celldex began an open-label, dose-escalation, U.S. Phase I trial to evaluate single and multiple doses of 0.1-10 mg/kg CDX-1127 in at least 30 patients with either solid tumors or hematologic cancers Celldex Therapeutics Inc. (NASDAQ:CLDX),...